Analyst Price Target Update on Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR): The mean short term price target for Nektar Therapeutics (NASDAQ:NKTR) has been established at $17.67 per share. The higher price target estimate is at $20 and the lower price target estimate is expected at $14 according to 6 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $2.42

For this week, the average consensus of the company shares are rated as a Strong Buy.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Nektar Therapeutics, Chess Robert had sold 5,000 shares worth of $77,500 in a transaction dated June 1, 2016. In this transaction, 5,000 shares were sold at $15.5 per share.

Nektar Therapeutics (NASDAQ:NKTR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.82 points or 5.19% at $14.98 with 1,111,254 shares getting traded. Post opening the session at $15.68, the shares hit an intraday low of $14.865 and an intraday high of $15.76 and the price was in this range throughout the day. The company has a market cap of $2,041 million and the number of outstanding shares have been calculated to be 136,262,720 shares. The 52-week high of Nektar Therapeutics (NASDAQ:NKTR) is $17.55 and the 52-week low is $9.16.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.